C
Charles Y. Lin
Researcher at Baylor College of Medicine
Publications - 128
Citations - 19573
Charles Y. Lin is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Transcription factor & Enhancer. The author has an hindex of 42, co-authored 116 publications receiving 15889 citations. Previous affiliations of Charles Y. Lin include Harvard University & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Abstract 2564: CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers
M. A. Day,Douglas C. Saffran,Tressa Hood,Nikolaus D. Obholzer,Akanksha Pandey,Charles Y. Lin,Pavan Kumar,Daniel M. Freed,Jorge F. DiMartino +8 more
TL;DR: Data show that transcriptionally addicted tumors are sensitive to CDK9 inhibition via KB-0742 treatment, and support the continued development of the compound to potentially treat sarcoma and chordoma.
Posted ContentDOI
Design of a systemic small molecule clinical STING agonist using physics-based simulations and artificial intelligence
Bryce K. Allen,Meghana M. Kulkarni,Brian Chamberlain,Timothy Dwight,Cheryl Koh,Ramya Samant,Finith E. Jernigan,Jamie Rice,Dazhi Tan,Stella Li,Kristen Marino,Evan L. Chiswick,Bethany Tesar,Sam Sparks,Zhixiong Lin,T. Dwight McGee,István Kolossváry,Charles Y. Lin,Sharon Shechter,Holly H. Soutter,Cecilia Bastos,Mohammed Taimi,Sujen Lai,A. A. Petrin,Tracy Kane,Steven L. Swann,Humphrey Gardner,Christopher Winter,Woody Sherman +28 more
TL;DR: The design of SNX281 is presented, a small molecule STING agonist that functions through a unique self-dimerizing mechanism in the STING binding site, where the ligand dimer approximates the size and shape of a cyclic dinucleotide while maintaining drug-like small molecule properties.
Peer ReviewDOI
Author response: Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng,Nicholas Kwiatkowski,Tinghu Zhang,Behnam Nabet,Mousheng Xu,Yanke Liang,Chunshan Quan,Jinhua Wang,Mingfeng Hao,Sangeetha Palakurthi,Shan Zhou,Qing Zeng,Paul Kirschmeier,Khyati Meghani,Alan L. Leggett,Jun Qi,Geoffrey I. Shapiro,Joyce F. Liu,Ursula A. Matulonis,Charles Y. Lin,Panagiotis A. Konstantinopoulos,Nathanael S. Gray +21 more
Journal ArticleDOI
Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC
Charles Y. Lin,Mariateresa Fulciniti,Michael A. Lopez,Mehmet Kemal Samur,Raphael Szalat,Christopher J. Ott,Christopher J. Ott,Charles B. Epstein,Richard A. Young,James E. Bradner,Kenneth C. Anderson,Nikhil C. Munshi,Nikhil C. Munshi +12 more
TL;DR: It is proposed that this oncogenic "re-wiring" accounts for the observed addiction of MM cells to lineage factors such as IRF4 and in this work, the B-cell factor TCF3 is implicate as a novel multiple myeloma dependency.